

TAV-mCD80-137L
TAV-mCD137L
TAV-mCD80
TAV-Δ19k
Anti-CD80
Anti-CD137L

FIGURE 1



TAV-mCD80-137L
TAV-mCD137L
TAV-mCD80
TAV-Δ19k
Anti-CD80
Anti-CD137L

FIGURE 2




FIGURE 3

FIGURE 4




FIGURE 5



WI-38
MRC5
A549
Anti-CD80
TAV-Δ19k
TAV-hCD80-137L
Anti-CD137L
TAV-Δ19k
TAV-hCD80-137L

FIGURE 6




FIGURE 7



No virus
TAV-hCD80-137L
MRC5
No virus
TAV-hCD80-137L
WI-38
No virus
TAV-hCD80-137L
A549
2
4
7
Days after infection

FIGURE 8




No virus
TAV-Δ19k
TAV-mCD80
TAV-mCD137L
TAV-mCD80-137L
2 4 7
Days after infection

FIGURE 9


1.0E+8
1.0E+7
1.0E+6
1.0E+5
Viral titer (PFU/ml)
Input
5 days after in-fection
TAV-19k
TAV-CD80
TAV-CD137L
TAV-CD80-137L



TAV-Δ19k
TAV-mCD80
TAV-mCD137L
TAV-mCD80-137L
Tumor volume (mm³)
300
250
200
150
100
50
0
0
5
10
15
20
25
Days after start of treatment

FIGURE 10



Tumor volume
300
250
200
150
100
50
0
0
10
20
30
40
50
60
Days after start of treatment
10⁷ PFU/dose
TAV-mCD80
TAV-mCD137L
TAV-mCD80-137L
Doses

FIGURE 11



Tumor volume (mm³)
600
400
200
0
0
5
10
15
Days after start of treatment
TAV-Δ19k
TAV-mCD80-137L

FIGURE 12

FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16A




FIGURE 16B





FIGURE 16C


TAV-mCD80-137L-ICAM
Tumor volume (mm³)
300
250
200
150
100
50
0
0
10
20
30
40
50
60
Day after start of treatment